Neuroprotection for amyotrophic lateral sclerosis: Role of stem cells, growth factors, and gene therapy

Central Nervous System Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 15-27

  Pandya, Rachna S ^a   Mao, Lilly L J ^b   Zhou, Edward W ^a   Bowser, Robert ^c   Zhu, Zhenglun ^a   Zhu, Yongjin ^a   Wang, Xin ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Pharma Medica Research Inc   (Canada)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Gene therapy; Growth factors; Neuroprotection; Physical exercise; Stem cells

Indexed keywords

ALPHA TOCOPHEROL; ANGIOGENIN; ANTISENSE OLIGONUCLEOTIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; COLIVELIN; COPPER ZINC SUPEROXIDE DISMUTASE; DRUG METABOLITE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; GROWTH HORMONE; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 206; MINOCYCLINE; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; NIMODIPINE; PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; RECOMBINANT VASCULOTROPIN; RILUZOLE; SCATTER FACTOR; SMALL INTERFERING RNA; SOMATOMEDIN C; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADIPOSE DERIVED STEM CELL; ADULT STEM CELL; AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE THERAPY; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; EMBRYONIC STEM CELL; EXCITOTOXICITY; EXERCISE; GENE MUTATION; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTONEURON; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NEURAL STEM CELL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLURIPOTENT STEM CELL; REVIEW; RNA INTERFERENCE; STEM CELL TRANSPLANTATION; SURVIVAL; VIRAL GENE DELIVERY SYSTEM;

EID: 84860505100     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152412800229152     Document Type: Review

References (133)

1. Kaspar, B. K. Mesenchymal stem cells as trojan horses for GDNF delivery in ALS. Mol. Ther., 2008, 16(12), 1905-1906.
2. Rowland, L. P.; Shneider, N. A. Amyotrophic lateral sclerosis. N. Engl. J. Med., 2001, 344(22), 1688-1700.
3. Bruijn, L.I.; Miller, T. M.; Cleveland, D. W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci., 2004, 27, 723-749.
4. Wang, H.; Guan, Y.; Wang, X.; Smith, K.; Cormier, K.; Zhu, S.; Stavrovskaya, I. G.; Huo, C.; Ferrante, R. J.; Kristal, B. S.; Friedlander, R. M. Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur. J. Neurosci., 2007, 26(3), 633-641.
5. Liu, J.; Akhavan, A.; Lu, M.; Gruzman, A.; Lingappa, V. R.; An, J.; Bowser, R. Carbonic anhydrase I is recognized by an SOD1 antibody upon biotinylation of human spinal cord extracts. Int. J. Mol. Sci., 2010, 11(10), 4051-4062.
6. Liu-Yesucevitz, L.; Bilgutay, A.; Zhang, Y. J.; Vanderwyde, T.; Citro, A.; Mehta, T.; Zaarur, N.; McKee, A.; Bowser, R.; Sherman, M.; Petrucelli, L.; Wolozin, B. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One, 2010, 5(10), e13250.
7. Wang, X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther., 2009, 15(4), 345-357.
8. Dodge, J. C.; Haidet, A. M.; Yang, W.; Passini, M. A.; Hester, M.; Clarke, J.; Roskelley, E. M.; Treleaven, C. M.; Rizo, L.; Martin, H.; Kim, S. H.; Kaspar, R.; Taksir, T. V.; Griffiths, D. A.; Cheng, S. H.; Shihabuddin, L. S.; Kaspar, B. K. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther., 2008, 16(6), 1056-1064.
9. Dodge, J. C.; Treleaven, C. M.; Fidler, J. A.; Hester, M.; Haidet, A.; Handy, C.; Rao, M.; Eagle, A.; Matthews, J. C.; Taksir, T. V.; Cheng, S. H.; Shihabuddin, L. S.; Kaspar, B. K. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther., 2010, 18(12), 2075-2084.
10. Lepore, A. C.; Haenggeli, C.; Gasmi, M.; Bishop, K. M.; Bartus, R. T.; Maragakis, N. J.; Rothstein, J. D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res., 2007, 1185, 256-265.
11. Li, M.; Ona, V. O.; Guegan, C.; Chen, M.; Jackson-Lewis, V.; Andrews, L. J.; Olszewski, A. J.; Stieg, P. E., Lee J. P.; Przedborski, S.; Friedlander, R. M. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science, 2000, 288(5464), 335-339.
12. Zhu, S.; Stavrovskaya, I. G.; Drozda, M.; Kim, B. Y.; Ona, V.; Li, M.; Sarang, S.; Liu, A. S.; Hartley, D. M.; Wu, D. C.; Gullans, S.; Ferrante, R. J.; Przedborski, S.; Kristal, B. S.; Friedlander, R. M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417(6884), 74-78.
13. Guan, Y. J., Wang, X., Wang, H. Y., Kawagishi, K., Ryu, H., Huo, C. F., Shimony, E. M., Kristal, B. S., Kuhn, H. G. and Friedlander, R. M., Increased stem cell proliferation in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice. J. Neurochem., 2007, 102(4), 1125-1138.
14. Rhodes, J.; Lutka, F. A.; Jordan-Sciutto, K. L.; Bowser, R. Altered expression and distribution of FAC1 during NGF-induced neurite outgrowth of PC12 cells. Neuroreport, 2003, 14(3), 449-452.
15. Towne, C.; Setola, V.; Schneider, B. L.; Aebischer, P. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol. Ther., 2011, 19(2), 274-283.
16. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med., 1994, 330(9), 585-591.
17. Cheah, B. C.; Vucic, S.; Krishnan, A. V.; Kiernan, M. C. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem., 2010, 17(18), 1942-1199.
18. Snow, R. J.; Turnbull, J.; da Silva, S.; Jiang, F.; Tarnopolsky, M. A. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience, 2003, 119(3), 661-667.
19. Waibel, S.; Reuter, A.; Malessa, S.; Blaugrund, E.; Ludolph, A. C. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol., 2004, 251(9), 1080-1084.
20. Del Signore, S. J.; Amante, D. J.; Kim, J.; Stack, E. C.; Goodrich, S.; Cormier, K.; Smith, K.; Cudkowicz, M. E.; Ferrante, R. J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler., 2009, 10(2), 85-94.
21. Chen, H. S.; Lipton, S. A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol., 1997, 499(Pt 1), 27-46.
22. Lipton, S. A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res., 2005, 2(2), 155-165.
23. Aracava, Y.; Pereira, E. F.; Maelicke, A.; Albuquerque, E. X. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther., 2005, 312(3), 1195-1205.
24. Levine, T. D.; Bowser, R.; Hank, N.; Saperstein, D. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph. Lateral Scler., 2010, 11(6), 514-519.
25. Kriz, J.; Gowing, G.; Julien, J. P. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol., 2003, 53(4), 429-436.
26. Graf, M.; Ecker, D.; Horowski, R.; Kramer, B.; Riederer, P.; Gerlach, M.; Hager, C.; Ludolph, A. C.; Becker, G.; Osterhage, J.; Jost, W. H.; Schrank, B.; Stein, C.; Kostopulos, P.; Lubik, S.; Wekwerth, K.; Dengler, R.; Troeger, M.; Wuerz, A.; Hoge, A.; Schrader, C.; Schimke, N.; Krampfl, K.; Petri, S.; Zierz, S.; Eger, K.; Neudecker, S.; Traufeller, K.; Sievert, M.; Neundorfer, B.; Hecht, M. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebocontrolled double-blind study. J. Neural. Transm., 2005, 112(5), 649-660.
27. Sanderink, G. J.; Bournique, B.; Stevens, J.; Petry, M.; Martinet, M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J. Pharmacol. Exp. Ther., 1997, 282(3), 1465-1472.
28. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4), 663-676.
29. Barker, N.; Bartfeld, S.; Clevers, H. Tissue-resident adult stem cell populations of rapidly self-renewing organs. Cell Stem Cell, 2010, 7(6), 656-670.
30. Maragakis, N. J. Stem cells and the ALS neurologist. Amyotroph. Lateral Scler., 2010, 11(5), 417-423.
31. Papadeas, S. T.; Maragakis, N. J. Advances in stem cell research for Amyotrophic lateral sclerosis. Curr. Opin. Biotechnol., 2009, 20(5), 545-551.
32. Wang, X.; Panyda, R.; Yao, J.; Ma, H.; Li, J. M. In: Neurodegeneration: Theory, Disorders and Treatments; A. S. McNeill, Ed.; NOVA Science Publishers, Inc.: New York. 2010; pp. 125-134.
33. Pandya, R.; Mao, L.; Zhou, H.; Zhou, S.; Zeng, J.; Popp, A. J.; Wang, X. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent. Nerv. Syst. Agents Med. Chem., 2011, 11(2), 81-97.
34. Naegele, J. R.; Maisano, X.; Yang, J.; Royston, S.; Ribeiro, E. Recent advancements in stem cell and gene therapies for neurological disorders and intractable epilepsy. Neuropharmacology, 2010, 58(6), 855-864.
35. Alvarez-Buylla, A.; Lois, C. Neuronal stem cells in the brain of adult vertebrates. Stem Cells, 1995, 13(3), 263-272.
36. Ma, D. K.; Bonaguidi, M. A.; Ming, G. L.; Song, H. Adult neural stem cells in the mammalian central nervous system. Cell Res., 2009, 19(6), 672-682.
37. de Filippis, L. Neural stem cell-mediated therapy for rare brain diseases: perspectives in the near future for LSDs and MNDs. Histol. Histopathol., 2011, 26(8), 1093-1109.
38. Mattis, V. B.; Svendsen, C. N. Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol., 2011, 10(4), 383-394.
39. Dimos, J. T.; Rodolfa, K. T.; Niakan, K. K.; Weisenthal, L. M.; Mitsumoto, H.; Chung, W.; Croft, G. F.; Saphier, G.; Leibel, R.; Goland, R.; Wichterle, H.; Henderson, C. E.; Eggan, K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 2008, 321(5893), 1218-1221.
40. Mitne-Neto, M.; Machado-Costa, M.; Marchetto, M. C.; Bengtson, M. H.; Joazeiro, C. A.; Tsuda, H.; Bellen, H. J.; Silva, H. C.; Oliveira, A. S.; Lazar, M.; Muotri, A. R.; Zatz, M. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum. Mol. Genet., 2011, 20(18), 3642-3652.
41. Di Giorgio, F. P.; Carrasco, M. A.; Siao, M. C.; Maniatis, T.; Eggan, K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci., 2007, 10(5), 608-614.
42. Wyatt, T. J.; Rossi, S. L.; Siegenthaler, M. M.; Frame, J.; Robles, R.; Nistor, G.; Keirstead, H. S. Human motor neuron progenitor transplantation leads to endogenous neuronal sparing in 3 models of motor neuron loss. Stem Cells Int., 2011, 207230.
43. Zhou, S. from bone to brain: human skeletal stem cell therapy for stroke. Cent. Nerv. Syst. Agents Med. Chem., 2011, 11(2), 157-163.
44. Mazzini, L.; Fagioli, F.; Boccaletti, R.; Mareschi, K.; Oliveri, G.; Olivieri, C.; Pastore, I.; Marasso, R.; Madon, E. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2003, 4(3), 158-161.
45. Karussis, D.; Karageorgiou, C.; Vaknin-Dembinsky, A.; Gowda-Kurkalli, B.; Gomori, J. M.; Kassis, I.; Bulte, J. W.; Petrou, P.; Ben-Hur, T.; Abramsky, O.; Slavin, S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol., 2010, 67(10), 1187-1194.
46. Gamez, J.; Carmona, F.; Raguer, N.; Ferrer-Sancho, J.; Martin-Henao G. A., Marti-Beltran, S.; Badia, M.; Gratacos, M.; Rodriguez-Gonzalez, E.; Seoane, J. L.; Pallero-Castillo, M.; Burgos, R.; Puiggros, C.; Pasarin, A.; Bori-Fortuny, I. Cellular transplants in amyotrophic lateral sclerosis patients: an observational study. Cytotherapy, 2010, 12(5), 669-677.
47. Pastor, D.; Viso-Leon, M. C.; Jones, J.; Jaramillo-Merchan, J.; Toledo-Aral, J. J.; Moraleda, J. M.; Martinez, S. Comparative Effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in a motorneuron degenerative mouse model. Stem Cell Rev., 2011, 19(2), 274-283.
48. Suzuki, M.; McHugh, J.; Tork, C.; Shelley, B.; Hayes, A.; Bellantuono, I.; Aebischer, P.; Svendsen, C. N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther., 2008, 16(12), 2002-2010.
49. Boucherie, C.; Caumont, A. S.; Maloteaux, J. M.; Hermans, E. in vitro evidence for impaired neuroprotective capacities of adult mesenchymal stem cells derived from a rat model of familial amyotrophic lateral sclerosis (hSOD1(G93A)). Exp. Neurol., 2008, 212(2), 557-561.
50. Gu, R.; Hou, X.; Pang, R.; Li, L.; Chen, F.; Geng, J.; Xu, Y.; Zhang, C. Human adipose-derived stem cells enhance the glutamate uptake function of GLT1 in SOD1(G93A)-bearing astrocytes. Biochem. Biophys. Res. Commun., 2010, 393(3), 481-486.
51. Blanquer, M.; Perez-Espejo, M. A.; Martinez-Lage, J. F.; Iniesta, F.; Martinez, S.; Moraleda, J. M. A surgical technique of spinal cord cell transplantation in amyotrophic lateral sclerosis. J. Neurosci. Methods, 2010, 191(2), 255-257.
52. Corti, S.; Nizzardo, M.; Nardini, M.; Donadoni, C.; Salani, S.; Simone, C.; Falcone, M.; Riboldi, G.; Govoni, A.; Bresolin, N.; Comi, G. P. Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum. Mol. Genet., 2010, 19(19), 3782-3796.
53. Wu, X.; Gao, H.; Ke, W.; Giese, R. W.; Zhu, Z. The homeobox transcription factor VentX controls human macrophage terminal differentiation and proinflammatory activation. J. Clin. Invest., 2011, 121(7), 2599-2613.
54. Carro, E.; Trejo, J. L.; Busiguina, S.; Torres-Aleman, I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J. Neurosci., 2001, 21(15), 5678-5684.
55. Carro, E.; Nunez, A.; Busiguina, S.; Torres-Aleman, I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci., 2000, 20(8), 2926-2933.
56. Gomez-Pinilla, F.; Ying, Z.; Opazo, P.; Roy, R. R.; Edgerton, V. R. Differential regulation by exercise of BDNF and NT-3 in rat spinal cord and skeletal muscle. Eur. J. Neurosci., 2001, 13(6), 1078-1084.
57. White, L. J.; Castellano, V. Exercise and brain health-implications for multiple sclerosis: Part 1-neuronal growth factors. Sports Med., 2008, 38(2), 91-100.
58. Cotman, C. W.; Berchtold, N. C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci., 2002, 25(6), 295-301.
59. Kirkinezos, I. G.; Hernandez, D.; Bradley, W. G.; Moraes, C. T. Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis. Ann. Neurol., 2003, 53(6), 804-807.
60. Kaspar, B. K.; Frost, L. M.; Christian, L.; Umapathi, P.; Gage, F. H. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis. Ann. Neurol., 2005, 57(5), 649-655.
61. Liebetanz, D.; Hagemann, K.; von Lewinski, F.; Kahler, E.; Paulus, W. Extensive exercise is not harmful in amyotrophic lateral sclerosis. Eur. J. Neurosci., 2004, 20(11), 3115-3120.
62. Carreras, I.; Yuruker, S.; Aytan, N.; Hossain, L.; Choi, J. K.; Jenkins, B. G.; Kowall, N. W.; Dedeoglu, A. Moderate exercise delays the motor performance decline in a transgenic model of ALS. Brain Res., 2010, 1313, 192-201.
63. Bello-Haas, V. D.; Florence, J. M.; Kloos, A. D.; Scheirbecker, J.; Lopate, G.; Hayes, S. M.; Pioro, E. P.; Mitsumoto, H. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology, 2007, 68(23), 2003-2007.
64. Drory, V. E.; Goltsman, E.; Reznik, J. G.; Mosek, A.; Korczyn, A. D. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J. Neurol. Sci., 2001, 191(1/2), 133-137.
65. Norris, F. H. Jr., Sang, U. K.; Denys, E. H.; Archibald, K. C.; Lebo, C. Amyotrophic lateral sclerosis. Mayo Clin. Proc., 1978, 53(8), 544.
66. Bohannon, R. W. Results of resistance exercise on a patient with amyotrophic lateral sclerosis. A case report. Phys. Ther., 1983, 63(6), 965-968.
67. Dalbello-Haas, V.; Florence, J. M.; Krivickas, L. S. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst. Rev., 2008, (2), CD005229.
68. Mahoney, D. J.; Rodriguez, C.; Devries, M.; Yasuda, N.; Tarnopolsky, M. A. Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis. Muscle Nerve, 2004, 29(5), 656-662.
69. Grundstrom, E.; Lindholm, D.; Johansson, A.; Blennow, K.; Askmark, H. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport, 2000, 11(8), 1781-1783.
70. Wehrwein, E. A.; Roskelley, E. M.; Spitsbergen, J. M. GDNF is regulated in an activity-dependent manner in rat skeletal muscle. Muscle Nerve, 2002, 26(2), 206-211.
71. Manabe, Y.; Nagano, I.; Gazi, M. S.; Murakami, T.; Shiote, M.; Shoji, M.; Kitagawa, H.; Abe, K. Glial cell line-derived neurotrophic factor protein prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Neurol. Res., 2003, 25(2), 195-200.
72. Li, W.; Brakefield, D.; Pan, Y.; Hunter, D.; Myckatyn, T. M.; Parsadanian, A.; Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp. Neurol., 2007, 203(2), 457-471.
73. Wang, Y. Q; Sun, F. Y. Neuroprotective mechanisms of vascular endothelial growth factor. Sheng Li Ke Xue Jin Zhan, 2007, 38(3), 202-207.
74. Zheng, C.; Skold, M. K.; Li, J.; Nennesmo, I.; Fadeel, B.; Henter, J. I. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem. Biophys. Res. Commun., 2007, 363(4), 989-993.
75. Storkebaum, E.; Lambrechts, D.; Dewerchin, M.; Moreno-Murciano, M. P.; Appelmans, S.; Oh, H.; Van Damme, P.; Rutten, B.; Man, W. Y.; De Mol, M.; Wyns, S.; Manka, D.; Vermeulen, K.; Van Den Bosch, L.; Mertens, N.; Schmitz, C.; Robberecht, W.; Conway, E. M.; Collen, D.; Moons, L.; Carmeliet, P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci., 2005, 8(1), 85-92.
76. Li, B.; Xu, W.; Luo, C.; Gozal, D.; Liu, R. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res. Mol. Brain Res., 2003, 111(1/2), 155-164.
77. Yabe, T.; Sanagi, T.; Yamada, H. The neuroprotective role of PEDF: implication for the therapy of neurological disorders. Curr. Mol. Med, 2010, 10(3), 259-266.
78. Kadoyama, K.; Funakoshi, H.; Ohya, W.; Nakamura, T. Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci. Res., 2007, 59(4), 446-456.
79. Chiba, T.; Hashimoto, Y.; Tajima, H.; Yamada, M.; Kato, R.; Niikura, T.; Terashita, K.; Schulman, H.; Aiso, S.; Kita, Y. Matsuoka, M. and Nishimoto, I., Neuroprotective effect of activitydependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo. J. Neurosci. Res, 2004, 78(4), 542-552.
80. Gurney, M. E.; Pu, H.; Chiu, A. Y.; Dal Canto, M. C.; Polchow, C. Y.; Alexander, D. D.; Caliendo, J.; Hentati, A.; Kwon, Y. W.; Deng, H. X.; Chen, W.; Zhai, P.; Sufit, R. L.; Siddique, T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science, 1994, 264(5166), 1772-1775.
81. Chiba, T.; Yamada, M.; Sasabe, J.; Terashita, K.; Aiso, S.; Matsuoka, M.; Nishimoto, I. Colivelin prolongs survival of an ALS model mouse. Biochem. Biophys. Res. Commun., 2006, 343(3), 793-798.
82. Wilczak, N.; de Vos, R. A.; de Keyser, J. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet, 2003, 361(9362), 1007-1011.
83. Kaspar, B. K.; Llado, J.; Sherkat, N.; Rothstein, J. D.; Gage, F. H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science, 2003, 301(5634), 839-842.
84. Dobrowolny, G.; Giacinti, C.; Pelosi, L.; Nicoletti, C.; Winn, N.; Barberi, L.; Molinaro, M.; Rosenthal, N.; Musaro, A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol., 2005, 168(2), 193-199.
85. Kunst, C. B. Complex genetics of amyotrophic lateral sclerosis. Am. J. Hum. Genet., 2004, 75(6), 933-947.
86. Kraemer, W. J.; Harman, F. S.; Vos, N. H.; Gordon, S. E.; Nindl, B. C.; Marx, J. O.; Gomez, A. L.; Volek, J. S.; Ratamess, N. A.; Mazzetti, S. A.; Bush, J. A.; Dohi, K.; Newton, R. U.; Hakkinen, K. Effects of exercise and alkalosis on serum insulin-like growth factor I and IGF-binding protein-3. Can. J. Appl. Physiol., 2000, 25(2), 127-138.
87. Lunn, J. S.; Hefferan, M. P.; Marsala, M.; Feldman, E. L. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors, 2009, 27(3), 133-140.
88. Phillips, H. S.; Hains, J. M.; Laramee, G. R.; Rosenthal, A.; Winslow, J. W. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science, 1990, 250(4978), 290-294.
89. Bengzon, J.; Kokaia, Z.; Ernfors, P.; Kokaia, M.; Leanza, G.; Nilsson, O. G.; Persson, H.; Lindvall, O. Regulation of neurotrophin and trkA, trkB and trkC tyrosine kinase receptor messenger RNA expression in kindling. Neuroscience, 1993, 53(2), 433-446.
90. Neeper, S. A.; Gomez-Pinilla, F.; Choi, J.; Cotman, C. W. Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res., 1996, 726(1/2), 49-56.
91. Neeper, S. A.; Gomez-Pinilla, F.; Choi, J.; Cotman, C. Exercise and brain neurotrophins. Nature, 1995, 373(6510), 109.
92. Rasmussen, P.; Brassard, P.; Adser, H.; Pedersen, M. V.; Leick, L.; Hart, E.; Secher, N. H.; Pedersen, B. K.; Pilegaard, H. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp. Physiol., 2009, 94(10), 1062-1069.
93. Katoh-Semba, R.; Asano, T.; Ueda, H.; Morishita, R.; Takeuchi, I. K.; Inaguma, Y.; Kato, K. Riluzole enhances expression of brainderived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J., 2002, 16(10), 1328-1330.
94. Iwasaki, Y.; Ikeda, K. Prevention by insulin-like growth factor-I and riluzole in motor neuron death after neonatal axotomy. J. Neurol. Sci., 1999, 169(1/2), 148-155.
95. Tsuchioka, M.; Hisaoka, K.; Yano, R.; Shibasaki, C.; Kajiatani, N.; Takebayashi, M. Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells. Brain Res., 2011, 1384, 1-8.
96. Morselli, L. L.; Bongioanni, P.; Genovesi, M.; Licitra, R.; Rossi, B.; Murri, L.; Rossi, G.; Martino, E.; Gasperi, M. Growth hormone secretion is impaired in amyotrophic lateral sclerosis. Clin. Endocrinol. (Oxf), 2006, 65(3), 385-388.
97. Sacca, F.; Quarantelli, M.; Rinaldi, C.; Tucci, T.; Piro, R.; Perrotta, G.; Carotenuto, B.; Marsili, A.; Palma, V.; De Michele, G.; Brunetti, A.; Brescia Morra, V.; Filla, A.; Salvatore, M. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. J. Neurol., 2011 Jun 25. [Epub ahead of print]. DOI:10.1007/s00415-011-6146-2.
98. Lai, E. C.; Felice, K. J.; Festoff, B. W.; Gawel, M. J.; Gelinas, D. F.; Kratz, R.; Murphy, M. F.; Natter, H. M.; Norris, F. H.; Rudnicki, S. A. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-1 Study Group. Neurology, 1997, 49(6), 1621-1630.
99. Suzuki, M.; and Svendsen, C. N. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci., 2008, 31(4), 192-198.
100. Xu, L.; Yan, J.; Chen, D.; Welsh, A. M.; Hazel, T.; Johe, K.; Hatfield, G.; Koliatsos, V. E. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation, 2006, 82(7), 865-875.
101. Corti, S.; Locatelli, F.; Papadimitriou, D.; Del Bo, R.; Nizzardo, M.; Nardini, M.; Donadoni, C.; Salani, S.; Fortunato, F.; Strazzer, S.; Bresolin, N.; Comi, G. P. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Brain, 2007, 130(Pt 5), 1289-1305.
102. Klein, S. M.; Behrstock, S.; McHugh, J.; Hoffmann, K.; Wallace, K.; Suzuki, M.; Aebischer, P.; Svendsen, C. N. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther., 2005, 16(4), 509-521.
103. Hwang, D. H.; Lee, H. J.; Park, I. H.; Seok, J. I.; Kim, B. G.; Joo, I. S.; Kim, S. U. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther., 2009, 16(10), 1234-1244.
104. Moreno-Igoa, M.; Manzano, R.; Olivan, S.; Calvo, A. C.; Toivonen, J. M.; Osta, R. Effects of gene therapy on muscle 18S rRNA expression in mouse model of ALS. BMC Res. Notes, 2010, 3, 275.
105. Park, S.; Kim, H. T.; Yun, S.; Kim, I. S.; Lee, J.; Lee, I. S.; Park, K. I. Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp. Mol. Med., 2009, 41(7), 487-500.
106. Dore, S.; Kar, S.; Quirion, R. Rediscovering an old friend, IGF-1: potential use in the treatment of neurodegenerative diseases. Trends Neurosci., 1997, 20(8), 326-331.
107. Dagvajantsan, B.; Aoki, M.; Warita, H.; Suzuki, N.; Itoyama, Y. Up-regulation of insulin-like growth factor-II receptor in reactive astrocytes in the spinal cord of amyotrophic lateral sclerosis transgenic rats. Tohoku J. Exp. Med., 2008, 214(4), 303-310.
108. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X.; Rahmani, Z.; Krizus, A.; McKenna-Yasek, D.; Cayabyab, A.; Gaston, S.M.; Berger, R.; Tanzi, R.E.; Halperin, J.J.; Herzfeldt, B.; van den Bergh, R.; Hung, W. Y.; Bird, T.; Deng, G.; Mulder, D. W.; Smyth, C.; Laing, N. G.; Soriano, E.; Pericak V. M.A.; Haines, J.; Rouleau, G.A.; Gusella, J.S.; Horvitz, H.R.; Brown Jr, R. H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362(6415), 59-62.
109. Cleveland, D. W.; Rothstein, J. D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci., 2001, 2(11), 806-819.
110. Kawamata, H.; Manfredi, G. Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech. Ageing Dev., 2010, 131(7/8), 517-526.
111. Prudencio, M.; Hart, P. J.; Borchelt, D. R.; Andersen, P. M. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum. Mol. Genet., 2009, 18(17), 3217-3226.
112. Deng, H. X.; Shi, Y.; Furukawa, Y.; Zhai, H.; Fu, R.; Liu, E.; Gorrie, G. H.; Khan, M. S.; Hung, W. Y.; Bigio, E. H.; Lukas, T.; Dal Canto, M. C.; O'Halloran, T. V.; Siddique, T. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. U.S.A., 2006, 103(18), 7142-7147.
113. Kabashi, E.; Valdmanis, P.N.; Dion, P.; Spiegelman, D.; McConkey, B. J.; Vande, C.; Bouchard, J. P.; Lacomblez, L.; Pochigaeva, K.; Salachas, F.; Pradat, P. F.; Camu, W.; Meininger, V.; Dupre, N.; Rouleau, G. A. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet., 2008, 40(5), 572-574.
114. Chen-Plotkin, A. S.; Lee, V. M.; Trojanowski, J. Q. TAR DNAbinding protein 43 in neurodegenerative disease. Nat. Rev. Neurol., 2010, 6(4), 211-220.
115. Zhou, H.; Huang, C.; Chen, H.; Wang, D.; Landel, C. P.; Xia, P. Y.; Bowser, R.; Liu, Y. J.; Xia, X. G. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet., 2010, 6(3), e1000887.
116. Kwiatkowski, T. J. Jr., Bosco, D. A.; Leclerc, A. L.; Tamrazian, E.; Vanderburg, C. R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E. J.; Munsat, T.; Valdmanis, P.; Rouleau, G. A.; Hosler, B. A.; Cortelli, P.; de Jong, P. J.; Yoshinaga, Y.; Haines, J. L.; Pericak-Vance, M. A.; Yan, J.; Ticozzi, N.; Siddique, T.; McKenna-Yasek, D.; Sapp, P. C.; Horvitz, H. R.; Landers, J. E.; Brown, R. H. Jr. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 2009, 323(5918), 1205-1208.
117. Deng, H. X.; Zhai, H.; Bigio, E. H.; Yan, J.; Fecto, F.; Ajroud, K.; Mishra, M.; Ajroud-Driss, S.; Heller, S.; Sufit, R.; Siddique, N.; Mugnaini, E.; Siddique, T. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol., 2010, 67(6), 739-748.
118. Amit, I.; Garber, M.; Chevrier, N.; Leite, A. P.; Donner, Y.; Eisenhaure, T.; Guttman, M.; Grenier, J. K.; Li, W.; Zuk, O.; Schubert, L. A.; Birditt, B.; Shay, T.; Goren, A.; Zhang, X.; Smith, Z.; Deering, R.; McDonald, R. C.; Cabili, M.; Bernstein, B. E.; Rinn, J. L.; Meissner, A.; Root, D. E.; Hacohen, N.; Regev, A. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science, 2009, 326(5950), 257-263.
119. Kieran, D.; Sebastia, J.; Greenway, M. J.; King, M. A.; Connaughton, D.; Concannon, C. G.; Fenner, B.; Hardiman, O.; Prehn, J. H. Control of motoneuron survival by angiogenin. J. Neurosci., 2008, 28(52), 14056-14061.
120. Takeuchi, S.; Fujiwara, N.; Ido, A.; Oono, M.; Takeuchi, Y.; Tateno, M.; Suzuki, K.; Takahashi, R.; Tooyama, I.; Taniguchi, N.; Julien, J. P.; Urushitani, M. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J. Neuropathol. Exp. Neurol., 2010, 69(10), 1044-1056.
121. Smith, R. A.; Miller, T. M.; Yamanaka, K.; Monia, B. P.; Condon, T. P.; Hung, G.; Lobsiger, C. S.; Ward, C. M.; McAlonis-Downes, M.; Wei, H.; Wancewicz, E. V.; Bennett, C. F.; Cleveland, D. W. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest, 2006, 116(8), 2290-2296.
122. Geng, C. M.; Ding, H. L. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles. Chin. Med. J. (Engl), 2011, 124(1), 106-110.
123. Maxwell, M. M.; Pasinelli, P.; Kazantsev, A. G.; Brown, R. H., Jr. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. Proc. Natl. Acad. Sci. U.S.A., 2004, 101(9), 3178-3183.
124. Yokota, T. Gene therapy of ALS with RNA interference. Rinsho Shinkeigaku, 2009, 49(11), 821-823.
125. Ralph, G. S.; Radcliffe, P. A.; Day, D. M.; Carthy, J. M.; Leroux, M. A.; Lee, D. C.; Wong, L. F.; Bilsland, L. G.; Greensmith, L.; Kingsman, S. M.; Mitrophanous, K. A.; Mazarakis, N. D.; Azzouz, M. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med., 2005, 11(4), 429-433.
126. Rizvanov, A. A.; Mukhamedyarov, M. A.; Palotas, A.; Islamov, R. R. Retrogradely transported siRNA silences human mutant SOD1 in spinal cord motor neurons. Exp. Brain Res., 2009, 195(1), 1-4.
127. Geng, C. M.; Ding, H. L. Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele. Acta, Pharmacol. Sin, 2008, 29(2), 211-216.
128. Xia, X.; Zhou, H.; Huang, Y.; Xu, Z.; Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol. Dis., 2006, 23(3), 578-586.
129. Prakash, S.; Malhotra, M.; Rengaswamy, V. Nonviral siRNA delivery for gene silencing in neurodegenerative diseases. Methods Mol. Biol., 2010, 623, 211-229.
130. Haramati, S.; Chapnik, E.; Sztainberg, Y.; Eilam, R.; Zwang, R.; Gershoni, N.; McGlinn, E.; Heiser, P. W.; Wills, A. M.; Wirguin, I.; Rubin, L. L.; Misawa, H.; Tabin, C. J.; Brown, R., Jr.; Chen, A.; Hornstein, E. miRNA malfunction causes spinal motor neuron disease. Proc. Natl. Acad. Sci. U.S.A., 2010, 107(29), 13111-13116.
131. Williams, A. H.; Valdez, G.; Moresi, V.; Qi, X.; McAnally, J.; Elliott, J. L.; Bassel-Duby, R.; Sanes, J. R.; Olson, E. N. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science, 2009, 326(5959), 1549-1554.
132. Lin, N.; Friedlander, R. M. Regeneration of neuromuscular synapses: action of microRNA-206. Neurosurgery, 2010, 66(4), N19-20.
133. Behrstock, S.; Svendsen, C. N. Combining growth factors, stem cells, and gene therapy for the aging brain. Ann. N. Y. Acad. Sci., 2004, 1019, 5-14.